Abstract
Background: The Step Forward Study (SFS) was designed to increase exercise activity and improve body mass index (BMI) among individuals with alpha-1 antitrypsin deficiency (AATD)-associated lung disease. Methods: The SFS is a randomized trial of an intensive distance intervention that was delivered via a series of mailings and teleconferences versus no additional intervention. All participants (n=500) were also enrolled in a disease management program designed for individuals with AATD-associated lung disease who have been prescribed augmentation therapy. The primary outcome was self-reported number of exercise minutes per week. The secondary outcome was body mass index (BMI). Linear mixed model analyses were used to assess the difference in average weekly exercise minutes between the intervention arms over time. T-tests, Signed Rank and Wilcoxon rank-sum tests were used to evaluate changes in BMI between the intervention arms and within each BMI category. Results: The study included 429 individuals with evaluable primary outcome data. There was a significant effect of intervention on exercise minutes over time (p=0.018). Participants in the intervention group reported an average of 167.14 minutes (SD=10.68) of weekly exercise and those in the standard care group reported 148.31 minutes (SD=10.96). There was a significant difference in BMI change between the intervention (mean BMI decrease 0.74, SD=2.16) and the standard care group (mean BMI decrease 0.27, SD=1.63); p=0.0122. Conclusions: Individuals who were randomly assigned to the intervention group reported more exercise activity and improvements in BMI over the course of this multicomponent intervention compared to individuals assigned to standard care.
Original language | English |
---|---|
Journal | Chronic Obstructive Pulmonary Diseases |
Volume | 8 |
Issue number | 1 |
DOIs | |
State | Published - 2020 |
Bibliographical note
Publisher Copyright:Copyright Chronic Obstructive Pulmonary Diseases: Journal of the COPD Foundation © 2020
Funding
income from AlphaNet. RC has received research support from AlphaNet. TB reports no conflicts. This work was funded by AlphaNet, Inc., United States. We are extremely grateful for the superb work of
Funders | Funder number |
---|---|
AlphaNet | |
AlphaNet, Inc. |
Keywords
- Alpha-1 antitrypsin deficiency
- Disease management
- Intensive distance intervention
- Step Forward Study
ASJC Scopus subject areas
- Pulmonary and Respiratory Medicine